VYNE Therapeutics Inc. (VYNE)

2.3000 -0.1000 (-4.17%) At close: 04:00PM EDT

VYNE Therapeutics Inc.

685 Route 202/206 N
Suite 301
Bridgewater, NJ 08807
United States
800 775 7936
https://www.vynetherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10

Key executives

Name	Title	Pay	Exercised	Year born
Mr. David T. Domzalski	CEO, President & Director	1.61M	N/A	1967
Dr. Iain A. Stuart Ph.D.	Chief Scientific Officer	856.82k	N/A	1973
Ms. Mutya Harsch J.D.	General Counsel, Chief Legal Officer & Company Secretary	817.97k	N/A	1975
Mr. Tyler Zeronda	CFO & Treasurer	N/A	N/A	1987
Dr. Darrell S. Rigel Faad, M.D., Ms	Consultant	40.2k	N/A	1951

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Corporate governance

VYNE Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.